Brief Papers
Cardiovascular risk in patients with new gout: should we reclassify the risk?
M. Gamala1, J.W. Jacobs2, S.P. Linn-Rasker3, M. Nix4, B.G. Heggelman5, P.C. Pasker-De jong6, J.M. Van Laar7, R. Klaasen8
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, and Department of Rheumatology, Northwest Clinics, Alkmaar and Den Helder, The Netherlands. m.gamala@umcutrecht.nl
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, The Netherlands.
- Department of Rheumatology, Meander Medical Center Amersfoort, The Netherlands.
- Department of Radiology, Meander Medical Center Amersfoort, The Netherlands.
- Department of Radiology, Meander Medical Center Amersfoort, The Netherlands.
- Meander Academy, Meander Medical Center Amersfoort, The Netherlands.
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, The Netherlands.
- Department of Rheumatology, Meander Medical Center Amersfoort, The Netherlands.
CER12488
2020 Vol.38, N°3
PI 0533, PF 0535
Brief Papers
Free to view
(click on article PDF icon to read the article)
PMID: 31820724 [PubMed]
Received: 09/06/2019
Accepted : 03/09/2019
In Press: 20/11/2019
Published: 26/05/2020
Abstract
OBJECTIVES:
Chronic inflammation, as seen in gout, may contribute to an increased risk of developing cardiovascular (CV) events (CVE). The aim of the study was to explore the effect of adding gout as a chronic inflammatory disease to the Dutch SCORE, a tool predicting 10-year CV mortality and morbidity.
METHODS:
This was a cross-sectional substudy including new patients with gout according the 2015 EULAR/ACR classification criteria who had participated in a trial on diagnostic accuracy of DECT with mono or oligoarthritis. Patients underwent a structured CV consultation, including assessment of CVE-history and of CV risk factors with the Dutch risk prediction SCORE. Chi-square test for trends was used to test for significance reclassification of the CV risk before and after adding gout to the Dutch SCORE.
RESULTS:
Seventy-six gout patients were included. SCORE was applied in 60 patients; 16 patients had experienced a prior CVE. The 10-year risk scores without gout as risk factor were high in 29 patients (48.3%), moderate in 6 (10%) and low in 25 (41.7%); with gout, the risk of 23/60 patients (38.3%) was reclassified from low to moderate in 6 patients (10%), from low to high in 11 (18.3%) and from moderate to high in 6 (10%), p<0.001 for trend.
CONCLUSIONS:
Adding gout to the risk prediction tools led to significant and clinically relevant reclassification of CV risk in new gout patients. Studies with large follow-up are warranted to validate these findings.
